ALSO NOTED: Vernalis reports "striking" weight loss in trial; Genmab shares surge on Phase III; FDA wants more time on Entereg;

> Vernalis is reporting "striking" weight loss results in its Phase I trial of the obesity drug V24343. Release 

> Shares of Genmab surged today after the company reported that it's pushing HuMax-EGFr (zalutumumab) into Phase III for head and neck cancer. Report 

> Adolor says that the FDA wants more time to review submissions before it decides on whether it will lift a clinical hold on Entereg for postoperative ileus. Report

> A new study of the breast cancer drug tamoxifen demonstrates that it not only works against bipolar disease, it also works faster than many standard therapies. Report

> Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America announced that the first patient has been enrolled in a Phase III study of lubiprostone for opioid-induced bowel dysfunction. Release

> Anesiva has initiated a new Phase II study of Adlea for the relief of post-operative pain in patients undergoing total knee replacement surgery. Release

> Trasylol got something of a reprieve yesterday when an FDA advisory panel recommended that it stay on the market. Report

> When does good news feel almost bad? When a blockbuster drug is deemed the juiciest on the market--but the wolves are circling. If this sounds like Lipitor to you, you're right. Report

And Finally… A U.S. biotech company, Yorktown Technologies, is seeking regulatory permission to import and sell fish that have been genetically modified to glow. Researchers have been developing the fish to identify contaminated waters--though it looks like there could be quite a market among exotic fish lovers. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.